Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab

Experimental and Therapeutic Medicine

Volumn 4, Issue 1, 2012, Pages 151-157

  Hong, Jidong ^a   Peng, Yuping ^a   Liao, Yuping ^a   Jiang, Wuzhong ^a   Wei, Rui ^a   Huo, Lei ^a   Han, Zaide ^a   Duan, Chaojun ^a   Zhong, Meizuo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Malignant gliomas; Nimotuzumab; Radiotherapy; Temozolomide

Indexed keywords

NIMOTUZUMAB; PLACEBO; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; CRANIOTOMY; DRUG DOSE INCREASE; DRUG SENSITIZATION; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTENSITY MODULATED RADIATION THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84865719997     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.555     Document Type: Article

References (48)

1. Counsell CE and Grant R: Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol 37: 241-250, 1998.
2. Nazzaro JM and Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73: 331-344, 1990.
3. Wood JR, Green SB and Shapiro WR: The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6: 338-343, 1988.
4. Albert FK, Forsting M, Sartor K, Adams HP and Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34: 45-61, 1994.
5. Devaux BC, O'Fallon JR and Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78: 767-775, 1993.
6. Curran WJ Jr, Scott CB, Horton J, et al: Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12: 219-227, 1992.
7. Walker MD, Alexander E Jr, Hun WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333-343, 1978.
8. Walker MD, Strike TA and Sheline GE: An analysis of doseeffect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5: 1725-1731, 1979.
9. Andersen AP: Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 17: 475-484, 1978.
10. Kristiansen K, Hagen S, Kollevold T, et al: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47: 649-652, 1981.
11. Laperriere N, Zuraw L and Cairncross G: Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64: 259-273, 2002.
12. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000.
13. Watkins JM, Marshall DT, Patel S, et al: High-dose radiotherapy to 78 Gy with or without temozolomide for high grade gliomas. J Neurooncol 93: 343-348, 2009.
14. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466, 2009.
15. Crombet T, Osorio M, Cruz T, et al: Use of the humanized antiepidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22: 1646-1654, 2004.
16. Rodriguez MO, Rivero TC, del Castillo Bahi R, et al: Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9: 343-349, 2010.
17. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the central nervous system. World Health Organization, IARC Press, Lyon, 2000.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
19. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet 361: 323-331, 2003.
20. Macdonald DR, Cascino TL, Schold SC Jr and Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
21. Berg G, Blomquist E and Cavallin-Stahl E: A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 42: 582-588, 2003.
22. Hegi ME, Diserens AC, Godard S, et al: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10: 1871-1874, 2004.
23. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004.
24. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
25. Diaz MA, Blanco R, Garcia B, et al: Biological activity in vitro of anti-epidermal growth factor receptor monoclonal antibodies with different affinities. Hybridoma (Larchmt) 26: 423-431, 2007.
26. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF and Collins VP: Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51: 2164-2172, 1991.
27. Bredel M, Pollack IF, Hamilton RL and James CD: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5: 1786-1792,1999.
28. Larysz D, Kula D, Kowal M, et al: Epidermal growth factor receptor gene expression in high grade gliomas. Folia Neuropathol 49: 28-38, 2011.
29. Qin D, Ou G, Mo H, et al: Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys 51: 959-962, 2001.
30. Van Vulpen M, Kal HB, Taphoorn MJ and El-Sharouni SY: Changes in blood-brain barrier permeability induced by radiotherapy: Implications for timing of chemotherapy? (Review). Oncol Rep 9: 683-688, 2002.
31. Cao Y, Tsien CI, Shen Z, et al: Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23: 4127-4136, 2005.
32. Ramos-Suzarte M, Rodriguez N, Oliva JP, et al: 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy. J Nucl Med 40: 768-775, 1999.
33. Ramos TC, Figueredo J, Catala M, et al: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 5: 375-379, 2006.
34. Giordano A, Rustum YM and Wenner CE: Cell cycle: molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer. J Cell Biochem 70: 1-7, 1998.
35. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151: 1523-1530, 1997.
36. Kerbel RS, Viloria-Petit A, Okada F and Rak J: Establishing a link between oncogenes and tumor angiogenesis. Mol Med 4: 286-295, 1998.
37. Gibson S, Tu S, Oyer R, Anderson SM and Johnson GL: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274: 17612-17618, 1999.
38. Lammering G, Hewit TH, Hawkins WT, et al: Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 93: 921-929, 2001.
39. Lammering G: Anti-epidermal growth factor receptor strategies to enhance radiation action. Curr Med Chem Anticancer Agents 3: 327-333, 2003.
40. Damiano V, Melisi D, Bianco C, et al: Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11: 5639-5644, 2005.
41. Diaz MA, Rolff J, Lemm M, Fichtner I, Perez R and Montero E: Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Br J Cancer 100: 950-958, 2009.
42. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59: 3374-3378, 1999.
43. Perrotte P, Matsumoto T, Inoue K, et al: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257-265, 1999.
44. Coleman CN and Stevenson MA: Biologic basis for radiation oncology. Oncology (Williston Park) 10: 399-415, 1996.
45. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J and Kumar R: Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273: 1568-1573, 1998.
46. Kwok TT and Sutherland RM: Cell cycle dependence of epidermal growth factor induced radiosensitization. Int J Radiat Oncol Biol Phys 22: 525-527, 1992.
47. Laderoute KR, Ausserer WA, Knapp AM, Grant TD and Sutherland RM: Epidermal growth factor modifies cell cycle control in A431 human squamous carcinoma cells damaged by ionizing radiation. Cancer Res 54: 1407-1411, 1994.
48. Huang SM and Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166-2174, 2000.